Revefenacin
Revefenacin is a long-acting muscarinic receptor antagonist (LAMA) designed for once-daily inhaled delivery that preferentially blocks M3 muscarinic receptors on bronchial smooth muscle, causing sustained bronchodilation and improved airflow in patients with chronic obstructive pulmonary disease. It is the first once-daily nebulized bronchodilator approved specifically for maintenance treatment of COPD.
Molecular Weight
597.7000 g/mol
LogP
4.10
TPSA
108.00 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D Structure
Cite this structure
Embed this structure
SMILES
CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1
InChI
InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
Molecular Formula
C35H43N5O4
HBD / HBA
2 / 6
Rotatable Bonds
11
Heavy Atoms
44
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Revefenacin is a long-acting muscarinic receptor antagonist (LAMA) designed for once-daily inhaled delivery that preferentially blocks M3 muscarinic receptors on bronchial smooth muscle, causing sustained bronchodilation and improved airflow in patients with chronic obstructive pulmonary disease. It is the first once-daily nebulized bronchodilator approved specifically for maintenance treatment of COPD.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Revefenacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3833319. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11753673. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="revefenacin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/revefenacin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/revefenacin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/revefenacin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="revefenacin"></drugfyi-drug>